Category - Developments

Closely-held AmorChem has spun out Mperia Therapeutics, a start-up company focusing on a novel immunotherapy approach based on CD36 cell receptor drug-ligands. All rights to the CD36 technology initially held by...

EyeGate Pharmaceuticals (NASDAQ:EYEG) has received an additional development milestone from a subsidiary of Valeant Pharmaceuticals International (NYSE, TSX:VRX). EyeGate previously granted Valeant exclusive, worldwide...

IntelGenx (OTCQX:IGXT; TSX-V:IGX) has entered into a licensing, development and supply agreement with closely-held Chemo Group, granting Chemo the exclusive license to commercialize two generic products for the U.S...

Episodic cluster headache patients using electroCore’s gammaCore non-invasive vagus nerve stimulation device (nVNS) had a significant and clinically meaningful benefit within 15 minutes of an attack treatment, compared...

Dipexium Pharmaceuticals (NASDAQ:DPRX) said that the European Patent Office has issued a new Locilex patent in the EU. The patent claims are directed to a novel formulation of Locilex, a topical antimicrobial peptide...

Tonix Pharmaceuticals Holding (NASDAQ:TNXP) said its Phase 3 AFFIRM study, designed to evaluate the safety and efficacy of TNX-102 SL in patients with fibromyalgia, did not achieve statistical significance in the...

Closely-held ASLAN Pharmaceuticals has licensed a novel immuno-oncology antibody, targeting RON (Recepteur d’Origine Nantais), from Singapore’s Agency for Science, Technology and Research (A*STAR). RON is a receptor...

Mesoblast (NASDAQ:MESO; ASX:MSB) appointed William Burns, a director, as vice chairman. In this role, Mr. Burns, a former CEO of Roche Pharmaceuticals from 2001 to 2009, will focus his considerable pharmaceutical...

Valeant Canada, a subsidiary of Valeant Pharmaceuticals International (NYSE, TSX: VRX), will commercialize Orexigen Therapeutics’ (NASDAQ:OREX) Contrave (naltrexone HCl / bupropion HCl extended release) in Canada. Under...

ARIAD Pharmaceuticals (NASDAQ:ARIA) has completed a rolling NDA submission to the FDA for its investigational anaplastic lymphoma kinase (ALK) inhibitor, brigatinib. ARIAD is seeking U.S. marketing approval of...